Project Cure CRC: Team Science Award

_NOTE: There are no application deadlines. Applications will be accepted on a rolling basis starting on January 25th._ _A response regarding your proposal submission will be provided within two months of submission_

About the Alliance

In 2010, the Alliance established the Chris4Life Research Program in honor of the late Christine Sapienza and for all the families who are affected by colorectal cancer. The research program was a critical driving force in the mission to end colorectal cancer in our lifetime. The Alliance has already invested nearly $10 million in colorectal cancer research, including nearly $3 million as early-stage grants to innovative researchers.

Project Cure CRC

The Colorectal Cancer Alliance (the Alliance) is pleased to announce a Request for Proposals (RFP) for preclinical and clinical translational research with the potential for high impact on diagnosis, treatment, or survivorship of colorectal cancer. Project Cure CRC will prioritize proposals that embrace moving colorectal cancer research to a curative science ASAP. Submitted proposals should focus on projects that are High-Risk/High-Reward and accelerate new therapies and technologies from bench to bedside. Projects that utilize collaborations and/or public-private partnerships are strongly encouraged. Proposals will be accepted for Early-Career Investigator Awards, Senior Investigator Awards, Pilot Awards, Team Science Awards, Opportunistic Awards and Strategic Awards from academic and industry researchers. The Alliance plans to award tens of millions this year  for new research and infrastructure needs arising from this RFP.

Research Objectives

Based on the Alliance’s Research Strategy and priorities identified at the Cure CRC Summit, Project Cure CRC welcomes proposals in the following areas:

* New strategies and technologies in immunotherapy and cellular therapy beyond MSI-H.
* Utilizing ctDNA and other liquid biopsies to improve MRD patient outcomes.
* Accelerating the development of antibody-drug conjugates therapies for CRC.
* Developing vaccine therapies for prevention of CRC recurrence, the effective utility to treat minimal residual disease, and as adjuvant therapies irrespective of tumor mutational status.
* Leveraging AI using existing large datasets and developing new datasets (molecular and clinical data) to advance precision medicine encompassing diagnostics, development of new treatments, treatment decisions, and longitudinal disease monitoring.
* Targeted therapies targeting cell signaling pathways towards a cure. Leveraging new target and treatment strategies in local and metastatic CRC.
* Developing effective cellular therapies for treatment of mCRC.
* Development of novel chemotherapeutic agents and combination therapies with increased efficacy and durable response while minimizing off-target effects.

Team Science Award

The Team Science Accelerator Award will support team science, including public- private partnerships, that will accelerate CRC research to curative science. Research proposals will be considered that accelerate new therapeutic and technology innovations from bench to bedside and address unmet clinical needs.

* Term: Two years
* Amount: Up to $250,000 per year for two years (up to $500,000 total)

Eligibility

_ You can learn more about this opportunity by visiting the funder's website.